study question: What is the expression pattern and functionality of caveolin 1 (CAV1) in the endometrium of patients with adenomyosis?
Introduction
Adenomyosis is a common gynecological disorder defined by the benign invasion of endometrial glands and stroma into the myometrium, whose pathogenesis remains poorly annotated (Ferenczy, 1998) . The clinical symptoms of this disease include dysmenorrhea, menorrhagia, metrorrhagia, early pregnancy-stage miscarriages or even subfertility. Adenomyosis management has been a major challenge, with hysterectomy being the treatment of choice. Even though adenomyosis is recognized as hormone sensitive, the use of progestogenic agents for its treatment fails to show satisfactory efficacy, which indicated the possibility of progesterone resistance in this disease. Other therapeutic options include gonadotrophinreleasing hormone agonists (GnRH-a) that could inhibit adenomyosis progression, yet their use is confined by short duration. Moreover, the symptoms often recur after discontinuation of GnRH-a therapy. Therefore, novel mechanisms of the pathogenesis of adenomyosis need to be unraveled that could be further manipulated to develop new therapeutic strategies for this disease.
In recent years, adenomyosis has been recognized as a metastatic disease (Chen et al., 2010; Zhou et al., 2012) . Endometrium derives from intermediate mesoderm via mesenchymal to epithelial transition during the development of the urogenital system (Matsuzaki and Darcha, 2012) . By retaining some imprint of their mesenchymal origin, endometrial epithelial cells (EECs) may be particularly prone to return to this state 'via' epithelial to mesenchymal transition (EMT). Loss of E-cadherin expression together with enhanced expression of mesenchymal markers, such as vimentin, is a hallmark of EMT. Previous studies have validated the occurrence of EMT in adenomyosis development that confers endometrial cells with increased migration and invasion capacity (Chen et al., 2010) . However, the molecular events underlying this process remain poorly understood.
Caveolin (CAV) proteins are the fundamental components of caveolae that form different structural and functional microdomains in a wide variety of cell types. Caveolae when associated with the plasma membrane demonstrate invaginations described as omegaor cave-like structures that cluster functionally related membraneassociated proteins. Hitherto, three CAV proteins have been identified, including caveolin-1 (CAV1, with splice variants a and b), caveolin-2 (CAV2) and caveolin-3 (CAV3). CAV1 and CAV2 have overlapping expression patterns in several cell types, including, neurons, glia, endothelial and epithelial cells (Luoma et al., 2008) . Although previous studies have proved that CAV1 played a crucial role in EMT as well as cell metastasis, the results remained inconsistent: Salem et al. proved that CAV1 could enhance pancreatic cancer cell differentiation and restore membranous E-cadherin via suppression of EMT (Salem et al., 2011) , whereas other researchers demonstrated that during EMT and metastasis, CAV1 is up-regulated via a variety of signaling pathways (Lu et al., 2003; Bailey and Liu, 2008; Salem et al., 2011; Huang et al., 2012) . In this study, we assumed that there might be abnormal expression of CAV1 in adenomyotic lesions and explored the expression and functionality of CAV1 in adenomyosis and its potential molecular mechanisms underlying adenomyosis-associated dysmenorrhea.
Materials and Methods

Sample collection
Paraffin-embedded ectopic and paired eutopic endometrial specimens were obtained from 65 patients who underwent surgical resections from 2009 to 2010 and had pathologically confirmed adenomyosis, among which 36 cases were in the proliferative phase and 29 cases were in the secretory phase. In addition, endometrial samples from 12 control women without related pathology were also included. Detailed clinicopathologic information of the patients is listed in Table 1 . This study was approved by the Institutional Ethics Committee of Sichuan University. Informed consents were obtained from all patients prior to analysis.
Immunohistochemical staining
Immunohistochemical staining was performed as described previously (Lei et al., 2011) . Briefly, sections were deparaffinized and rehydrated in graded ethanols. After rinsing in distilled water, sections were microwaved for 5 min at 600 W in 0.01 mol/l sodium citrate buffer (pH 6.0); this step was then repeated four times. The slides were immersed in 3% H 2 O 2 in distilled water for 5 min and then in blocking solution (0.01 mol/l Tris, 0.3% Triton X-100, 1% bovine serum albumin and 3% normal goat serum) for 30 min to block endogenous peroxidase activity and unspecific binding sites, respectively. Sections were further rinsed in Tris-buffered saline and incubated at 48C overnight with the primary antibody CAV1 (Santa Cruz Technology, Santa Cruz, CA, USA, 1:150 dilution) and RANTES (R&D Systems, Minneapolis, MN, USA, 1:200 dilution), followed Loss of stromal caveolin-1 expression in human adenomyosis discrepancy between the two evaluators was resolved by reevaluation and careful discussion until agreement was reached.
Primary endometrial stromal cell (ESC) and EEC culture, drug treatment and transfection
Isolation of primary endometrial stromal cells (ESCs) and EECs was performed as described previously (Yang et al., 2007) , and the background of the six additional patients without related pathology from whom the samples for culture experiments were collected is listed in Table 2 . These cells were cultured in media consisting of M199 and F12 (1:1) with added Mitoplus TM (2 ml/l) (Collaborative Biomedical Products, Bedford, MA, USA), bovine pituitary extract (2 ml/l) (Collaborative Biomedical Products), ITS+ [containing insulin (0.62 ng/ml), transferrin (0.62 mg/ml) and selenium (0.62 ng/ml)] (Collaborative Biomedical Products) and antibiotic and antimycotic agents. ESCs for analysis were treated with methyl-b-cyclodextrin (MbCD) (5 mM) (Sigma-Aldrich, Oakville, Ontario, Canada), a CAV1 antagonist or water for 24 h. As for small interfering RNA (siRNA) analysis, siRNA oligonucleotides with specificity for CAV1 and non-targeting siRNA were designed as described previously (Sofia Martins et al., 2011) and were obtained from GenePharma (Shanghai, China). siRNA oligonucleotides with specificity for RANTES and non-targeting siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ANXA2-plasmid encoding fulllength human ANXA2 was purchased from Integrated Biotech Solutions (Shanghai, China) based on the cDNA sequence of ANXA2 (GenBank TM accession number NM_001753). It was further ligated into the BamHI-EcoRI sites of the pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA, USA) to construct the CAV1 expression plasmid pcDNA3.1/ CAV1. The correct orientation and sequence of the insert were verified by DNA sequencing. Either siRNA or the pcDNA3.1/CAV1 plasmid was transfected into ESCs cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Western blotting
For western blotting analysis, the whole-cell lysates were prepared as described previously (Li et al., 2010a,b) . Primary antibodies included: CAV1 (Santa Cruz Biotechnology), RANTES (R&D Systems), extracellular-signal-regulated kinase (ERK) (Cell Signaling Technology, Boston, MA, USA), p-ERK (Cell Signaling Technology), FAK (Cell Signaling Technology) and p-FAK (Cell Signaling Technology). Signals were quantified by QuantityOne software (Bio-Rad, Hercules, CA, USA) and defined as the ratio of target protein to b-actin.
Cell proliferation assays
Cell proliferation was evaluated using a combination of methylthiazolydiphenyl-tetrazolium (MTT) assay and colony formation assay. As for MTT assay, cells were seeded at 5 × 10 3 cells/well in 96-well plates and cultivated in 100 ml medium. Culture wells were set up in triplicate for each treatment, and the assay was carried out as described previously (Li et al., 2008) . As for colony formation assay, 100 counted cells were seeded in triplicate in a 6-well plate, respectively, and cultured with medium continuously for 14 days. Subsequently, clones were stained with Giemsa and counted under a microscope. A cluster with more than 50 cells was considered as a clone, and clonogenic formation rate was calculated.
Transwell cell migration/invasion assay
Transwell 24-well chambers (Corning, Corning, NY, USA) were used for in vitro cell migration and invasion assays. For the evaluation of migration, cells were plated in the upper chamber with RPMI1640 medium containing 0.5% fetal bovine serum. Conditioned medium of primary ESCs pretreated with MbCD or a combination of siRANTES and MbCD or cells transfected with siCAV1 and pcDNA3.1/CAV1 was added to the lower chamber as chemoattractant. EECs were seeded (1 × 10 5 cells) in 100 ml suspension in the upper chamber and incubated at 378C in air with 5% CO 2 for 48 h. Filters were then removed, stained with crystal violet, and the cells of five fields were counted using an inverted microscope (Zeiss axiovert). To monitor cell invasion, the upper side of the filter was covered with Matrigel (Collaborative Research Inc., Boston, MA, USA), and the treatments were similar to those used to assess cell migration. After 72 h of the invasion assay, cells on the upper side of the filter were removed. Cells that remained adherent to the underside of the membrane were fixed and stained with crystal violet. Each experiment was performed in triplicate, and 10 contiguous fields of each sample were examined to obtain a representative number of cells that had migrated/invaded across the membrane. The results of the migration/invasion assays were normalized to the proliferation for each group.
Cytokine analysis
Cytokine production in the culture supernatant was assessed using Human Cytokine Array kit (R&D Systems) according to the manufacturer's instructions.
Measurement of nitrite/nitrate and prostaglandin E2 (PGE2) production
The total gas phase nitric oxide (NO) (nitrite/nitrate) in the culture medium of primary ESCs was assessed using a NO colorimetric assay kit (#k262, BioVision, Milpitas, CA, USA) according to the manufacturer's instructions. The prostaglandin E2 (PGE2) levels of the cell lysates were determined using an enzyme-linked immunosorbent assay kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's protocol.
Pain assessment
Pain assessment was conducted in 40 adenomyosis patients (these 40 patients fell into those 65 patients whose endometrial tissues were further subjected to immunohistochemical analysis) as described previously (Nie et al., 2010) . Briefly, questionnaires on dysmenorrhea and other clinical information were administered before surgery during the hospital stay. Pain assessment was done with a 10-point linear analog scale, with 0 representing no pain and 10 representing the worst possible pain. Moreover, the severity of dysmenorrhea was classified as mild (pain, but no interference with routine daily life or work and no need for analgesics), moderate (pain interfering with routine daily life or work to some extent and relief of pain after taking analgesics) and severe (pain seriously interfering routine with daily life or work and no relief of pain after taking analgesics) as described previously (Nie et al., 2010) .
Statistical analysis
Data are presented as mean + SD of three independent experiments unless otherwise indicated. GraphPad Prism (GraphPad Software Inc., CA, USA) was used for data analysis. The comparison of distributions of continuous variables was made using the Wilcoxon test or KruskalWallis test. Jonckheere-Terpstra trend test was utilized to test for trend of stromal CAV1 and RANTES immunoreactivity in women reporting more severe dysmenorrhea as described previously (Nie et al., 2010) . The correlation between stromal CAV1 and RANTES staining scores and dysmenorrhea scores was analyzed using 'Pearson's' x 2 test. Comparisons between two groups were performed with the Student's t-test, and differences among multiple groups were evaluated by one-way ANOVA analysis. Differences were considered statistically significant at P , 0.05.
Results
Differential stromal CAV1 expression in ectopic and paired eutopic endometrium in human adenomyosis
To investigate the potential role of CAV1 in adenomyosis development, we examined the expression of CAV1 in the ectopic endometrium and paired eutopic endometrium of adenomyosis patients and control endometrium using immunohistochemistry analysis. We found that in 12 normal endometrial tissues and 65 sets of paired ectopic and eutopic endometrium of adenomyosis, no immunoreactivity of CAV1 could be observed in endometrial glandular cells. However, in the normal endometrial tissues and the eutopic endometrium of adenomyosis, the immunoreactivity of CAV1 was primarily restricted to the membrane of ESCs. In the paired ectopic endometrium of adenomyosis, stromal CAV1 immunoreactivity could rarely be observed regardless of either proliferative phase or secretory phase (n ¼ 65, P , 0.001; Fig. 1A and B). These data implicated that CAV1 is down-regulated in the ESCs of human adenomyosis.
Loss of stromal CAV1 expression increases proliferation of EECs and promotes metastasis of both ESCs and EECs in adenomyosis
To further explore the functional role of loss of stromal CAV1 in adenomyosis development, we suppressed the expression of CAV1 in primary ESCs by either transfection with CAV1 siRNA or treatment with MbCD, an established CAV1 inhibitor (Sofia Martins et al., 2011) and then examined the phenotypes of CAV1-low ESCs and their impact on the biological behavior of EECs. We observed downregulation of CAV1 expression in ESCs transfected with CAV1 siRNA and those treated with MbCD when compared with respective controls ( Fig. 2A) . Next, we evaluated whether suppression of CAV1 in ESCs could influence proliferation and metastasis of ESCs. Interestingly, no significant increase in proliferation of ESCs was observed upon CAV1 inhibition (data not shown), whereas EECs incubated with MbCD-treated ESC-conditioned media demonstrated accelerated proliferation as measured by MTT assay. Likewise, CAV1 siRNAtransfected ESC-conditioned media resulted in a faster proliferation rate of EECs when compared with negative control siRNA (siNC)-transfected ESC-conditioned media-incubated cells (Fig. 2B) . In addition, CAV1-low-ESC-conditioned medium significantly enhanced colony-forming capacity of EECs when compared with control groups (P , 0.05, Fig. 2C and D) . In contrast, EECs incubated with pcDNA3.1/CAV1 plasmid-transfected ESC-conditioned media demonstrated a retarded proliferation rate, as demonstrated by the MTT assay (P , 0.05, Fig. 3A ) and colony formation assay (P , 0.05, Fig. 3B ). However, the migration and invasion potential of both ESCs and EECs did not significantly change after pcDNA3.1/ CAV1 plasmid transfection (data not shown). These data demonstrated that loss of stromal CAV1 expression could lead to enhanced proliferation of EECs. We further examined whether loss of stromal CAV1 expression could influence the metastatic behaviors of both ESCs and EECs. Our results showed that MbCD treatment significantly increased migrating capacity of ESCs (P , 0.05, Fig. 4A) . Moreover, using a Transwell chamber invasion assay, we further observed a significant elevation in the invasive capacity of ESCs treated with MbCD when compared with control (P , 0.05, Fig. 4B ). Similarly, we noted that incubation with MbCD-treated ESC-conditioned media resulted in a significantly increased number of EECs with greater migrating and invasive capacity (P , 0.05, Fig. 4C and D) . However, no significant changes were observed in the migration and invasion capacity of both pcDNA3.1/CAV1-transfected ESCs and EECs incubated with pcDNA3.1/CAV1 plasmid-transfected ESC-conditioned media (data not shown). Taken together, these results implied that loss of stromal CAV1 expression could confer endometrial cells with enhanced metastatic capacity.
Loss of stromal CAV1 expression triggers RANTES release in ESCs of adenomyosis
To analyze the underlying mechanisms of loss-of-stromal-CAV1-induced adenomyosis pathogenesis, we examined the concentration of a panel of pro-inflammatory cytokines in ESCs treated with MbCD or ESCs transfected with siCAV1. The levels of six inflammatory cytokines were significantly increased in the supernatant of ESCs treated with MbCD, including TNF-a, IL-6, monocyte chemoattractant protein-1, IL-8, RANTES and IL-10 (Fig. 5A) . Furthermore, cytokine assays revealed that IL-1b, IFNg-induced protein-10 (IP-10), IL-6, IL-10, RANTES and IL-17 were significantly altered in ESCs transfected with siCAV1 (Fig. 5B) . Interestingly, RANTES was significantly increased in both ESCs treated with MbCD and ESCs transfected with siCAV1 (2.54-fold and 3.30-fold increase, respectively). These data suggested that loss of stromal CAV1 expression in endometrium could result in a pro-inflammatory microenvironment that might be conducive to the development of adenomyosis.
Because the RANTES expression is up-regulated in both ESCs treated with MbCD and ESCs transfected with siCAV1, we further explored the expression pattern of RANTES in the endometrium of adenomyosis patients by immunohistochemistry. In the normal endometrial tissues and the eutopic endometrium of adenomyosis patients, the immunoreactivity of RANTES is nearly undetectable in both stroma and glandular epithelium. In the paired ectopic endometrium of adenomyosis, however, stromal RANTES immunoreactivity is significantly increased when compared with either their eutopic counterparts or normal endometrial tissues (n ¼ 65, P , 0.01; Fig. 6A and B) . Therefore, RANTES release in ESCs induced by loss of stromal CAV1 might play a role in adenomyosis formation.
Loss of stromal CAV1 induces endometrial metastasis via stromal RANTES release
To investigate whether the biological effects of CAV1-low ESCs could be reversed by RANTES inhibition, we transfected MbCD-pretreated ESCs with either siRANTES or siNC and evaluated the invasion and migration of these ESCs and their influence on the metastatic behavior of EECs. Our data demonstrated that, although not significant, the number of MbCD-pretreated ESCs transfected with siRANTES (ESC siRANTES ) that migrated to the lower chamber of the Transwell was lower than that of those transfected with siNC (ESC siNC ) (P . Fig. 7A ). On the other hand, incubation with MbCD-pretreated ESC siRANTES -conditioned media resulted in a significantly decreased
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Loss of stromal caveolin-1 expression in human adenomyosis number of EECs that migrated to the lower chamber when compared with control (P , 0.05, Fig. 7B ). Furthermore, using the Transwell chamber invasion assay, we further observed a significant decrease in the invasive capacity of MbCD-pretreated ESC siRANTES when compared with control (P , 0.05, Fig. 7C ). Likewise, incubation with MbCD-pretreated ESC siRANTES -conditioned media resulted in a significantly reduced number of EECs with greater invasive capacity (P , 0.05, Fig. 7D ). Taken together, these data implicated that RANTES might play a critical role in the enhanced metastatic capacity of endometrial cells induced by loss of stromal CAV1 in adenomyosis patients. Transwell invasion assay of EECs was performed using 24-well transwells after 72 h of plating. ESC were pretreated directly with MbCD, whereas EECs were pretreated with MbCD-treated ESC-conditioned medium. All the data are the mean value obtained from the samples of three different patients and they are from at least three independent experiments (shown as mean + SD). *P , 0.05. EECs, endometrial epithelial cells; ESCs, endometrial stromal cells; MbCD, methyl-b-cyclodextrin.
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Stromal CAV1 and RANTES expression in ectopic endometrium is correlated with dysmenorrhea severity in adenomyosis patients
We further examined whether stromal CAV1 and RANTES expression in ectopic endometrium is correlated with dysmenorrhea severity in adenomyosis patients. Our results demonstrated that ectopic stromal CAV1 expression was significantly lower in adenomyosis patients who reported severe dysmenorrhea than those reporting no, mild or moderate dysmenorrhea (P , 0.05, Fig. 8B ). 'Pearson's' correlation analysis identified a negative correlation between stromal CAV1 expression (adjusted by menstrual phase) in ectopic endometrium and dysmenorrhea scores in 40 adenomyosis patients with statistical significance (r 2 ¼ 0.1549; P ¼ 0.012, 'Pearson's' x 2 test; Fig. 8A ). On the other hand, ectopic stromal RANTES expression was significantly higher in adenomyosis patients with severe dysmenorrhea than those in other groups (P , 0.05, Fig. 8D ). 'Pearson's' correlation analysis revealed a positive correlation between stromal RANTES expression (adjusted by menstrual phase) in ectopic endometrium and dysmenorrhea scores in 40 adenomyosis patients with statistical significance (r 2 ¼ 0.1549; P ¼ 0.012, 'Pearson's' x 2 test; Fig. 8C ). Collectively, our results implied that stromal CAV1 and RANTES expression in ectopic endometrium are correlated with dysmenorrhea severity in adenomyosis patients.
Loss of CAV1 induces increased NO and PGE2 release and is associated with ERK-FAK signaling pathway activation
To investigate the potential mechanisms underlying adenomyosisassociated dysmenorrhea by loss of stromal CAV1 expression, we further examined the levels of two well-established pain mediators, namely NO and PGE2, in CAV1-depleted and control ESCs. Transfection of CAV1 siRNA in ESCs significantly increased NO and PGE2 production by 3.67-and 3.78-fold, respectively (P ¼ 0.146 and P ¼ 0.0028, respectively; Fig. 9 ). Therefore, release of NO and PGE2 in CAV-1-depleted ESCs could be a potential cause for adenomyosisassociated dysmenorrhea. Recent reports have correlated the ERK-FAK signaling pathway with cell motility and invasion (Sawhney et al., 2006; Li et al., 2010a,b) . To examine whether loss of CAV1 in ESCs could induce downstream ERK-FAK pathway activation, we analyzed the expression of ERK, p-ERK, FAK and p-FAK in ESCs transiently transfected with siCAV1. After 48 h, cell lysates were prepared and subjected to immunoblot analysis. In ESCs, knockdown of CAV1 could significantly increase the levels of phosphorylated ERK and FAK (Fig. 10A) . Moreover, the relative p-ERK to total ERK ratio and the relative p-FAK to total FAK ratio were both significantly increased in ESCs transfected with siCAV when compared with control (Fig. 10B) . Taken together, our results showed that loss of stromal CAV1 expression is associated with ERK-FAK signaling pathway activation.
Discussion
The process of adenomyosis development is similar to tumor metastasis that is defined by progressive transmyometrial invasion of endometrium to form ectopic lesions. However, the molecular mechanisms responsible for its pathogenesis remain largely unknown. Hitherto, only a few molecular events have been characterized that might be responsible for adenomyosis development, including decreased immunoreactivity to progesterone receptor isoform B (Nie et al., 2009) and increased immunoreactivity to annexin A2 , nuclear factor kB (Nie et al., 2009) , oxytocin receptor (Nie et al., 2010) , vasopressin-1a receptor (Mechsner et al., 2010) , SLIT/ ROBO1 (Nie et al., 2011) and transient receptor potential vanilloid type 1 (Nie et al., 2010) in the ectopic epithelium when compared with control. Their expression levels were tightly correlated with dysmenorrhea severity in adenomyosis patients, which are either directly or indirectly linked to inflammation and other pain mediators. Nevertheless, no studies have characterized the functional role of ESCs in the pathogenesis of adenomyosis and their impact on adenomyosis-associated dysmenorrhea. In the present study, we demonstrated that loss of stromal CAV1 expression was frequently observed in the ectopic endometrium of adenomyosis patients. Functional studies revealed that loss of stromal CAV1 expression promotes ESC metastasis and enhances growth and metastasis of EECs, possibly via triggering RANTES release. Stromal RANTES expression level was significantly higher in the ectopic endometrium of adenomyosis patients than in the eutopic endometrium. Inhibition of RANTES in Transwell invasion assay of EECs was performed using 24-well transwells after 72 h of plating. ESCs were pretreated with MbCD, whereas EECs were pretreated with MbCD-treated ESC. All the data were the mean value obtained from the samples of three different patients and they were from at least three independent experiments (shown as mean + SD). *P , 0.05. CAV1, calveolin-1; MbCD, methyl-b-cyclodextrin; ESCs, endometrial stromal cells; EECs, endometrial epithelial cells.
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ESCs could inhibit metastatic capacity of ESCs with down-regulated CAV1 expression. Moreover, both loss of stromal CAV1 expression and elevated expression of stromal RANTES were correlated with dysmenorrhea severity in adenomyosis patients. Furthermore, downregulation of stromal CAV1 may cause severe dysmenorrhea via the release of two well-established pain mediators, NO and PGE2. ERK-FAK signaling pathway was also proved to be activated in ESCs with low CAV1 level. Thus, our study has provided novel insights into the underlying mechanisms of adenomyosis pathogenesis.
Caveolae are 50-100 nm large plasma membrane invaginations morphologically different from the classical clathrin-coated vesicles that were initially identified by electron microscopy (Kiss and Botos, 2009 ). So far, three different caveolin genes (CAV1, CAV2 and CAV3) have been identified that encode for the structural depleted and control ESCs. All the data are the mean value obtained from the samples of three different patients and they are from at least three independent experiments (shown as mean + SD). *P , 0.05; **P , 0.01. NO, nitric oxide; PGE2, prostaglandin E2; ESCs, endometrial stromal cells.
components of these organelles. CAV1 is the best studied of the three caveolins, and it is considered a multifunctional scaffold protein involved in caveolae biogenesis, cholesterol homeostasis, intracellular trafficking and signal transduction, among other functions (Boscher and Nabi, 2012) . In addition, CAV1 has been implicated in the modulation of several cancer-associated phenotypes, including cell proliferation, death and transformation (Burgermeister et al., 2008; Goetz et al., 2008) . However, the precise role of CAV1 in tumorigenesis remains controversial and whether it acts as a tumor suppressor or as a promoter of metastasis seems to be cell type and contextspecific. On the one hand, there are several lines of clinical and genetic evidence that demonstrates CAV1 as a tumor suppressor. It was found that CAV1 is down-regulated and/or mutated in a variety of human malignancies, including mammary adenocarcinomas (Sotgia et al., 2006) and squamous cell carcinomas (Zhang et al., 2008) . Moreover, although CAV1-knockout mice do not develop spontaneous tumors, they are more susceptible to carcinogen [7,12-dimethylbenz(a) anthracene]-and oncogene-induced cancer in skin (Capozza et al., 2003) and mammary tissues , respectively. On the other hand, the notion that CAV1 serves as a 'general' tumor suppressor has been challenged by studies showing that CAV1 expression is cancer type and/or stage dependent. CAV1 is up-regulated in the bladder, colon, esophagus, thyroid (papillary subtype), hepatic and prostate carcinomas, and this up-regulation seems to be associated with multidrug resistance and/or metastasis (Williams and Lisanti, 2005) . Consistently, CAV1 was reported to enhance cell migration and invasiveness (Urra et al., 2012) . However, the role of stromal CAV1 in tumorigenesis has been more definitive because accumulating evidence proved that stromal CAV1 expression is down-regulated in a variety of tumor cell types, including breast cancer (Goetz et al., 2011) , metastatic melanoma (Wu et al., 2011) and advanced prostate cancer (Di Vizio et al., 2009) . Loss of stromal CAV1 expression has been linked to oxidative stress, inflammation, hypoxia challenge and stem cell phenotype in the tumor microenvironment that initiates and maintains the malignant behaviors of tumor cells (Pavlides et al., 2010) . Although so far no reports have demonstrated that loss of CAV1 expression in stroma could lead to pain under pathologic conditions, Pavlides's study indirectly linked loss of stromal CAV1 expression with pain because the transcriptional profile of CAV1(2/2) stromal cells, when compared with wild-type stromal cells, included up-regulation of a series of proinflammatory molecules and pain mediators (Pavlides et al., 2010) . Correspondingly, our results demonstrated that CAV1 expression in the ESCs of adenomyosis patients is significantly down-regulated and might be responsible for adenomyosis-associated dysmenorrhea.
The stromal cells are a critical component of the ectopic tissues of adenomyosis because the interaction between epithelium and stroma plays a key role in driving endometrial cell invasiveness and progression. Recent studies using implantation models of endometrial cells suggest that ESCs participate in the attachment and early invasion into the peritoneum (Yoshida et al., 2004) . Thus, the invasion of ESCs through the peritoneal surface is an essential step in the development of this disease. More importantly, ESCs also interact with other cell types to facilitate pathogenesis of endometriosis and adenomyosis. For instance, Klinkova et al. examined the communication between cultured monocytes and ESCs using DNA microarray (Klinkova et al., 2010) . On the one hand, treatment of ESCs with monocyte-conditioned medium caused significant changes in the expression of many genes. On the other hand, ESCs could secrete factors that modified gene expression in monocytes. Interestingly, four of the genes that were differentially expressed (either increased or decreased) in ESCs in response to monocyte-conditioned medium were also differentially expressed in monocytes in response to ESC-conditioned medium: de-etiolated 1, calpain 3, plasminogen activator inhibitor 1 and H1 histone family member 0. However, there is only a limited number of studies demonstrating the interaction between EECs and stroma. Our studies reported that CAV1-depleted ESCs demonstrated enhanced metastatic potential and they further facilitated growth, migration and invasion of EECs. These effects were possibly achieved through RANTES secretion by ESCs.
RANTES (also termed CCL5), a chemokine for monocytes and activated T cells, has been reported to actively regulate increased inflammatory and proliferative responses in women with endometriosis (Hornung et al., 1997 ). Moreover, RANTES expression level was found to be elevated in peritoneal fluid of women with endometriosis and was correlated with the clinical stage of the disease (Hornung et al., 2001 ). More interestingly, Yang et al. recently reported that elevated immunoreactivity of RANTES and CCR1 significantly correlates with the severity of stages and dysmenorrhea in women with deep infiltrating endometriosis (DIE), particularly DIE-related pelvic pain (Yang et al., 2012) . However, no studies have characterized the expression pattern of RANTES expression in adenomyosis, and the relationship between the expression of RANTES and CAV1 in ESCs remains unannotated. In our study, we initially found that RANTES was up-regulated in ESCs treated with both siCAV1 and MbCD. Further studies demonstrated that stromal RANTES expression level was significantly higher in the ectopic endometrium of adenomyosis patients when compared with that in the eutopic counterpart. Inhibition of RANTES in ESCs could inhibit motility and invasion of ESCs and EECs. Expression of stromal RANTES was positively correlated with dysmenorrhea severity in adenomyosis patients. Thus, the current study characterized the effect of RANTES on motility and invasion of endometrial cells and proved that RANTES might be a downstream molecular event of loss of stromal CAV1 expression in the formation of adenomyosis.
Accumulating evidence indicates that NO contributes to the processing of nociceptive transduction in the spinal cord, and a number of in vivo studies have consistently shown that inhibition of NO synthesis could remarkably decrease both inflammatory and neuropathic pain (Meller and Gebhart, 1993; Luo and Cizkova, 2000) . It has been demonstrated that NO synthesis is significantly increased in endometriosis (Osborn et al., 2002) and adenomyosis (Oh et al., 2012) . In our study, we found that silencing of CAV1 in ESCs increased NO production, suggesting that loss of CAV1 in adenomyotic stromal cells may facilitate NO release. On the other hand, PGE2 has been reported to sensitize nociceptors and transduce stimulation into a pain signal, thus facilitating pain transmission and perception (Kawabata, 2011) . Moreover, the increase in PGE2 production in endometriosis has long been reported (Sacco et al., 2012) . Current medical therapies for endometriosis, including the use of combined oral contraceptives, danazol, GnRH analogs, progestins and nonsteroidal anti-inflammatory drugs, primarily target PGs and, thus, reduce endometriosis-associated dysmenorrhea (Wu et al., 2010) . These are indirect evidence for the role of PGE2 as a pain mediator. The finding that inhibition of CAV1 expression in ESCs increased the PGE2 production suggested that stromal CAV1 down-regulation might also contribute to the increased PGE2 production in adenomyosis. The elevated release of both NO and PGE2 in ectopic lesions of adenomyosis patients might be the cause for adenomyosis-associated dysmenorrhea.
Taken together, our study demonstrated that decreased expression of CAV1 was observed in the ectopic ESCs of adenomyosis patients. Loss of stromal CAV1 expression enhanced metastasis of ESCs and enabled increased growth, migration and invasion of EECs that might involve the release of RANTES in the stroma of the ectopic lesion. The expression level of RANTES in the ectopic ESCs of adenomyosis patients was significantly higher than that in the eutopic counterpart, and RNAi-mediated RANTES suppression in ESCs could inhibit metastatic capacity of CAV1-low ESCs. Moreover, both stromal CAV1 loss and stromal RANTES up-regulation in the ectopic endometrium were correlated with dysmenorrhea severity in adenomyosis patients. Silencing of stromal CAV1 in ESCs could trigger NO and PGE2 production in ESCs, potentially contributing to the symptom of dysmenorrhea. Taken together, these results suggest that loss of stromal CAV1 expression may play a critical role in the pathogenesis of adenomyosis and is associated with adenomyosis-related dysmenorrhea.
